Genzyme Corp. (Sanofi Genzyme) has disclosed sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, among others.
The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback